PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of cviPermissionsJournals.ASM.orgJournalAEM ArticleJournal InfoAuthorsReviewers
 
Clin Vaccine Immunol. 2012 June; 19(6): 825–834.
PMCID: PMC3370435

Live Oral Typhoid Vaccine Ty21a Induces Cross-Reactive Humoral Immune Responses against Salmonella enterica Serovar Paratyphi A and S. Paratyphi B in Humans

Abstract

Enteric fever caused by Salmonella enterica serovar Paratyphi A infection has emerged as an important public health problem. Recognizing that in randomized controlled field trials oral immunization with attenuated S. enterica serovar Typhi live vaccine Ty21a conferred significant cross-protection against S. Paratyphi B but not S. Paratyphi A disease, we undertook a clinical study to ascertain whether humoral immune responses could explain the field trial results. Ty21a immunization of adult residents of Maryland elicited predominantly IgA antibody-secreting cells (ASC) that recognize S. Typhi lipopolysaccharide (LPS). Cross-reactivity to S. Paratyphi A LPS was significantly lower than that to S. Paratyphi B LPS. ASC producing IgG and IgA that bind LPS from each of these Salmonella serovars expressed CD27 and integrin α4β7 (gut homing), with a significant proportion coexpressing CD62L (secondary lymphoid tissue homing). No significant differences were observed in serum antibody against LPS of the different serovars. Levels of IgA B memory (BM) cells to S. Typhi LPS were significantly higher than those against S. Paratyphi A or B LPS, with no differences observed between S. Paratyphi A and B. The response of IgA BM to outer membrane proteins (OMP) from S. Typhi was significantly stronger than that to OMP of S. Paratyphi A but similar to that to OMP of S. Paratyphi B. The percentages of IgG or IgA BM responders to LPS or OMP from these Salmonella strains were similar. Whereas cross-reactive humoral immune responses to S. Paratyphi A or B antigens are demonstrable following Ty21a immunization, they cannot explain the efficacy data gleaned from controlled field trials.

INTRODUCTION

Enteric fevers are caused by the human-restricted pathogens Salmonella enterica serovar Typhi, S. enterica serovar Paratyphi A, and S. Paratyphi B (and rarely S. Paratyphi C). S. Typhi is estimated to cause up to 33 million cases of typhoid fever and 600,000 deaths each year worldwide (9, 10). S. Paratyphi A illness (paratyphoid A fever) is on the rise both in areas of endemicity (10, 13) and among travelers returning from regions of endemicity or epidemicity (10, 43), and the cases are increasingly caused by multidrug-resistant strains (48). Because there are no vaccines currently available to prevent enteric fevers other than typhoid fever, the development of vaccines against paratyphoid A (and perhaps paratyphoid B) fevers is a public health priority (18).

Currently, two licensed vaccines against typhoid fever (parenteral Vi polysaccharide and oral attenuated S. Typhi strain Ty21a) are available. Vi polysaccharide vaccine induces serum anti-Vi antibodies (33). However, because S. Paratyphi A and S. Paratyphi B do not express the Vi antigen, the Vi vaccine will not protect against these pathogens. In contrast, the licensed live oral Ty21a typhoid vaccine (Ty21a), derived from wild-type strain S. Typhi Ty2, has the potential to elicit cross-protection against paratyphoid fevers A and B, given the close homology in many key antigenic determinants between these Salmonella serovars. A few published epidemiological and retrospective studies have explored Ty21a's possible cross-protective immunity with S. Paratyphi A and S. Paratyphi B infections. Results from two large-scale, randomized, placebo-controlled, double-blind (thus “gold-standard”) field trials indicate that Ty21a provides significant protection against S. Paratyphi B disease but not against S. Paratyphi A disease (3, 37, 43, 57). Two efficacy trials of Ty21a conducted in Santiago, Chile, indicated that Ty21a conferred protection from S. Typhi and moderate protection against paratyphoid B infections (3, 36, 37). Because few cases of paratyphoid A fever occurred during the performance of these trials, it was not possible to draw conclusions about whether Ty21a also provided partial protection against S. Paratyphi A (37). Observations from a large randomized placebo-controlled field trial in Plaju, Indonesia, strongly suggested that Ty21a is unable to confer cross-protection against S. Paratyphi A infection (57). In contrast, a retrospective study by Meltzer et al. among travelers from Israel to the Indian subcontinent suggested that Ty21a might confer some protection against S. Paratyphi A (42). However, in a subsequent report the authors stated that current typhoid vaccines offer no protection against S. Paratyphi A (43). Taken together, these studies strongly suggest that the currently available oral vaccine against typhoid fever either provides no protection or is not sufficiently effective against S. Paratyphi A.

The development of broad-spectrum live oral vaccines against the major etiologic agents causing enteric fevers will benefit from an in-depth understanding of the immunological mechanisms that are involved in the protection conferred by Ty21a against S. Typhi and the observed cross-protection against S. Paratyphi B. Whereas detailed studies of the immunological responses following immunization with Ty21a have been performed with S. Typhi, whether these immunological responses extend to S. Paratyphi A or B has not been addressed. Results from these studies suggest that the induction of specific IgA antibody-secreting cells (ASC) that recognize S. Typhi lipopolysaccharide (LPS) and the induction of memory B (BM) cells that recognize S. Typhi LPS might be among the effector mechanisms predictive of or involved in protection (15, 27, 31, 6669, 71). It remains unknown whether these vaccine-induced humoral responses actually mediate protection or serve as a surrogate for the presence of other immune responses, such as cell-mediated immune responses (CMI), which may be more critical in mediating and conferring long-term protection. In this study, we evaluated the cross-reactive humoral immune responses against S. Paratyphi A and S. Paratyphi B induced following Ty21a vaccination by measuring ASC (which included the characterization of their homing potential, for which very little is known), serum antibodies (Ab), and BM cells before and after vaccination.

MATERIALS AND METHODS

Subjects, vaccination, and specimen collection.

The study was approved by the University of Maryland Institutional Review Board. Healthy adult volunteers were recruited from the Baltimore-Washington, DC, area and University of Maryland, Baltimore, community. Prior to enrollment, the purpose of the study was explained to the subjects, and informed consent was obtained from all participants. Their medical histories were reviewed, and physical and laboratory examinations were performed to ensure that they were in good health. Any volunteer who had a history of typhoid fever or immunization against typhoid fever was excluded from participation. Seventeen subjects (8 male and 9 female, 20 to 51 years old) were enrolled and vaccinated with four spaced doses of 2 × 109 to 6 × 109 viable CFU of Ty21a (Vivotif enteric-coated capsules [Crucell] administered within an 8-day period) (14). Blood was collected before immunization (day 0) and on days 7, 42, 84, and 180 postvaccination to obtain serum and peripheral blood mononuclear cells (PBMC). The clinical research guidelines of the U.S. Department of Health and Human Services and those of the University of Maryland, Baltimore, were followed in the conduct of the present clinical research.

Preparation of Salmonella lipopolysaccharide (LPS) and outer membrane protein (OMP) antigens. (i) Bacterial strains.

S. Paratyphi A strain CVD 1902 and S. Typhi Ty21a have been described previously (16, 17). S. Paratyphi B strain CV 163 is a ΔguaBA deletion mutant derived from a clinical isolate from Chile (M. M. Levine, unpublished data). Strains were grown in animal product-free LB Lennox medium (Athena ES, Baltimore, MD). Growth in liquid medium was performed overnight in flasks at 37°C and 250 rpm, followed by harvesting by centrifugation at 7,000 × g at 4°C.

(ii) LPS.

S. Typhi LPS was purchased from Sigma (St. Louis, MO) (catalog no. L-7136), and S. Paratyphi A LPS and S. Paratyphi B LPS were obtained from S. Paratyphi A CVD 1902 and S. Paratyphi B CV 163, respectively, by the extraction method of Darveau and Hancock, with the addition of a final phenol purification step (11, 20). Purified LPS was resuspended in pyrogen-free water to a concentration of 20 mg/ml and stored at −70°C until used.

(iii) OMP.

S. Typhi, S. Paratyphi A, and S. Paratyphi B OMPs were prepared from the strains described above by the method described by Nikaido (45), except that the final chromatography step was omitted to retain a heterogenous mixture of OMP. Final OMP preparations were dialyzed against phosphate-buffered saline (PBS) in 3.5 kDa-molecular-mass-cutoff dialysis cassettes (Thermo, Waltham, MA) and kept at 4°C for subsequent analyses. Protein concentrations were assessed by bicinchoninic acid (BCA) assay (Thermo) normalized to bovine serum albumin (BSA) standards. The relative protein composition was assessed by SDS-PAGE and Coomassie blue staining (Thermo Gelcode Blue). The identity of the expected proteins in the OMP preparations (e.g., porins) was confirmed by tryptic digestion and mass spectrometric analysis conducted at the University of Maryland Medical School Proteomics Core facility.

ASC assays.

IgG and IgA antibody-secreting cells (ASC) recognizing LPS from the three Salmonella serovars were measured in circulating PBMC before and 7 days after immunization with Ty21a. A positive response was defined as an ASC count equal or greater than 8 spot-forming cells (SFC) per 106 PBMC as previously described (66, 67).

Flow cytometric determination of the expression of homing molecules and sorting of PBMC B cell subsets to measure ASC recognizing LPS.

Flow cytometric measurements of the expression of homing molecules and the sorting protocol for isolating B cell subsets expressing different homing molecules were described previously (12). Briefly, freshly isolated PBMC obtained prevaccination (day 0) and 7 days postvaccination were stained with monoclonal antibodies (MAb) to CD19-phycoerythrin (PE)-Cy7 (clone J3-119; Beckman Coulter, Indianapolis, IN), CD27-PE-Cy5 (clone 1A4CD27; Beckman Coulter), CD62L-PE (L-selectin, clone Dreg-56; BD Biosciences, San Diego, CA), and integrin a4b7 (clone ACT-1) conjugated to Alexa 488 using an Alexa labeling kit (Molecular Probes, Carlsbad, CA). Cells were then simultaneously sorted into 4 populations: B naive (Bn) (CD19+ CD27) or B memory (BM) (CD19+ CD27+) expressing CD62L but not integrin α4β7 (BM lymph node [LN]) (CD62L+ integrin α4β7), BM expressing integrin α4β7 but not CD62L (BM gut) (CD62L integrin α4β7+), or BM expressing both integrin α4β7 and CD62L (BM LN/gut) (CD62L+ integrin α4β7+). Four-way sorting was performed in a MoFlo flow cytometer/cell sorter system (Beckman-Coulter). Purities of the sorted populations were 86% to 96% (the gating strategy is shown in Fig. S1 in the supplemental material). IgG and IgA ASC recognizing S. Typhi, S. Paratyphi A, and S. Paratyphi B LPS in each sorted population were measured as described above.

Serum Ab assays.

IgG and IgA serum antibodies (Ab) to S. Typhi, S. Paratyphi A, and S. Paratyphi B LPS were measured by enzyme-linked immunosorbent assay (ELISA) (71). Endpoint titers were calculated through linear regression as the inverse of the serum dilution that produces an optical density (OD) of 0.2 above the value for the blank. Postvaccination fold increases of anti-LPS Ab titers were calculated as titers postvaccination divided by the corresponding prevaccination titers × 100. Seroconversion was defined as a ≥4-fold increase in postvaccination Ab titer at any time point (day 7 or 42) postvaccination compared to prevaccination.

IgA BM ELISpot assay.

The method used for the enzyme-linked immunosorbent spot (ELISpot) assay has been described previously (7). Briefly, frozen PBMC were thawed and expanded with B cell expansion medium consisting of 5 μM β-mercaptoethanol (β-ME) (Bio-Rad, Hercules, CA), 1:100,000 pokeweed mitogen (kindly provided by S. Crotty), 6 μg/ml CpG-2006 (Sigma), and 1:10,000 Staphylococcus aureus Cowan (Sigma) in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin (CellGro, Manassas, VA), 50 μg/ml gentamicin (HyClone, Logan, UT), 2 mM l-glutamine, 2.5 mM sodium pyruvate, 10 mM HEPES, and 10% heat-inactivated fetal bovine serum (BioWhittaker, Walkersville, MD) (complete RPMI). Cells were expanded for 5 days (1.5 × 106 cells/well in 6-well plates). Supernatants were collected for antibody-in-lymphocyte-supernatant (ALS) measurements, and expanded PBMC were used immediately in BM ELISpot assays by seeding them on nitrocellulose plates (Mahan; Millipore, Billerica, MA) coated with S. Typhi, S. Paratyphi A, or S. Paratyphi B LPS (10 μg/ml) or OMP (5 μg/ml) or total goat anti-human IgA (Jackson ImmunoResearch Lab, West Grove, PA) (5 μg/ml) diluted in PBS as described previously (71).

Adequate expansion of BM cells was assessed by the frequency of total IgA detected by ELISpot assay as described previously (71). Any specimen that had fewer spot-forming cells (SFC) than the 5th percentile of the total IgA SFC per 106 expanded PBMC (3,965/106 cells) was excluded from analysis. One volunteer was excluded from the analysis based on this criterion. As described, a cutoff for postvaccination responders was defined as an increase in antigen-specific BM per total IgA SFC that was equal or greater than 0.05% above baseline (day 0) in any subject.

Measurement of ALS of BM cultures.

In the culture supernatants collected after 5 days of expansion for BM assay (see “IgA BM ELISpot assay” above), IgG and IgA antibodies against S. Typhi, S. Paratyphi A, and S. Paratyphi B LPS and OMP were measured by ELISA as described above. Positive responders by ALS were defined as those subjects who exhibited an increase of at least 2-fold in the specific Ab titers at any of the postvaccination times (day 42, 84, or 180) compared to their corresponding prevaccination levels (day 0).

Statistical analysis.

Statistical comparisons were carried out using nonparametric Wilcoxon matched-pair or Mann-Whitney U tests as indicated. Correlations between two parameters were examined by Spearman's correlation. Differences with P values of <0.05 (two tailed) were considered significant. Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, La Jolla CA).

RESULTS

Induction in Ty21a vaccinees of ASC that recognize S. Typhi, S. Paratyphi A, and S. Paratyphi B LPS.

The appearance of antigen-specific ASC within the first week after immunization with attenuated oral vaccines, including Ty21a, is often used as a parameter to evaluate immunogenicity. To determine whether there is cross-reactivity to LPS purified from S. Typhi, S. Paratyphi A, and S. Paratyphi B, we measured the presence of specific IgA and IgG ASC before immunization and on day 7 postvaccination using PBMC immediately after isolation from Ty21a vaccinees. Out of 17 volunteers recruited, PBMC from one volunteer were not available on day 7 for ASC measurements. As shown in Fig. 1A, IgA ASC responses that recognize S. Typhi LPS (median, 47/106 PBMC) were detected in 13 out of 16 (81%) volunteers in their day 7 postvaccination specimens compared to the corresponding prevaccination levels. Similarly, 12 out of 16 volunteers (75%) exhibited IgA ASC responses that recognized S. Paratyphi A and S. Paratyphi B LPS (median, 27 and 45.5/106 PBMC, respectively). However, the magnitude (mean ± standard error [SE]) of the LPS IgA ASC responses directed to S. Typhi was significantly higher than that to S. Paratyphi A or S. Paratyphi B LPS, and the magnitude of the responses to S. Paratyphi B was significantly higher than that to S. Paratyphi A (Fig. 1A and Table 1).

Fig 1
Specific antibody-secreting cells (ASC) in Ty21a vaccinees. Levels of IgA (A) and IgG (B) ASC specific to lipopolysaccharide (LPS) from S. Typhi, S. Paratyphi A (Para A), and S. Paratyphi B (Para B) in Ty21a vaccinees (n = 16) before and 7 days after ...
Table 1
LPS ASC responses to S. Typhi, S. Paratyphi A, and S. Paratyphi B

We also measured the IgG ASC responses to the different LPS antigens in these specimens (Fig. 1B). The percentage of positive responders for IgG ASC that recognize S. Typhi LPS (median, 22/106 PBMC), observed in 11 out of 16 (69%) was higher, albeit not statistically significantly, than that of positive responders for IgG ASC recognizing S. Paratyphi A LPS (median, 6/106 PBMC), observed in 7 out of 16 (44%), or S. Paratyphi B LPS (median, 11.5/106 PBMC), observed in 8 out of 16 (50%). However, the magnitude of IgG ASC responses to S. Typhi LPS was significantly higher than that to S. Paratyphi A LPS but not significantly different from that to S. Paratyphi B LPS (Fig. 1B and Table 1). The IgG ASC responses to S. Paratyphi B, albeit somewhat higher than those to S. Paratyphi A, did not reach statistical significance (Table 1). IgA ASC responses predominated over the corresponding IgG ASC responses to S. Typhi, S. Paratyphi A, and S. Paratyphi B LPS (Table 1).

Characterization of LPS-specific ASC homing patterns.

Since the gut microenvironment is the first line of defense against enteric diseases, we investigated the homing characteristics of the ASC that recognize LPS induced by immunization with Ty21a. To study the homing potential of circulating ASC, we sorted fresh PBMC obtained 7 days after immunization with Ty21a into four distinct subpopulations of CD19+ B cells. The gating and purity of the sorted populations are shown in Fig. S1 in the supplemental material. Sorted B cell subsets were immediately plated in S. Typhi LPS-coated plates as described in Materials and Methods. ASC frequencies for each of the subpopulations revealed that virtually all IgA and IgG ASC that recognize LPS were observed in the BM (CD19+ CD27+) subset (Fig. 2A and andD).D). The majority of IgA and IgG ASC recognizing LPS were observed among BM cells that expressed the gut homing molecule integrin α47 in the absence of CD62L (BM gut; i.e., endowed with the potential to home to the gut). However, it is important to note that significant proportions of both IgG and IgA ASC recognizing LPS were also observed among CD19+ CD27+ CD62L+ α4β7+ cells, which appear to have the capacity to home to both the gut and peripheral lymphoid tissues (BM LN/gut). Virtually no ASC were observed in plates seeded with Bn cells (CD19+ CD27) or BM cells that expressed the lymph node homing receptor CD62L in the absence of integrin α4β7 (BM LN) (Fig. 2A and andDD).

Fig 2
Homing characteristics of ASC in Ty21a vaccinees. Shown are IgA (A, B, and C) and IgG (D, E, and F) ASC specific for LPS from S. Typhi (A and D), S. Paratyphi A (B and E), and S. Paratyphi B (C and F) in sorted subsets from 4 individual Ty21a vaccinees. ...

We next explored the possibility that differences in the homing characteristics of ASC elicited following immunization with Ty21a that are reactive to S. Paratyphi A and S. Paratyphi B LPS preparations could help explain the observed moderate cross-protection to infections with S. Paratyphi B, but not to S. Paratyphi A, reported for Ty21a vaccinees. As can be seen in Fig. 2, no differences were observed in the homing characteristics of the various IgA and IgG ASC B cell subsets recognizing LPS from S. Typhi (Fig. 2A and andD),D), S. Paratyphi A (Fig. 2B and andE),E), or S. Paratyphi B (Fig. 2C and andFF).

Induction of serum Ab to S. Typhi, S. Paratyphi A, and S. Paratyphi B LPS in Ty21a vaccinees.

We next evaluated whether there were differences in the serum antibody levels to LPS from S. Typhi, S. Paratyphi A, and S. Paratyphi B following Ty21a vaccination. Sera were collected before (day 0) and 7 and 42 days following immunization. The mean serum Ab titers against LPS from S. Typhi, S. Paratyphi A, and S. Paratyphi B were significantly elevated on days 7 and 42 postvaccination compared to their prevaccination levels, with the highest levels observed in day 7 samples (Fig. 3). Postvaccination fold increases of anti-LPS IgA Ab titers declined markedly from day 7 to day 42 (Fig. 3A). No significant differences were observed in the seroconversion rates for IgA Ab titers against S. Typhi (8 out of 17; 47%), S. Paratyphi A (6 out of 17; 35%), and S. Paratyphi B (6 out of 17; 35%) LPS. Similarly, no differences were observed in the mean ± SE of the peak postvaccination (from either day 7 or 42) IgA Ab fold increases against S. Typhi, S. Paratyphi A, and S. Paratyphi B LPS antigens (Table 2).

Fig 3
LPS-specific serum antibody responses in Ty21a vaccinees. Shown are postvaccination fold increases in serum anti-LPS antibodies to S. Typhi-, S. Paratyphi A (Para A)-, and S. Paratyphi B (Para B)-specific IgA (A) and IgG (Panel B) in Ty21a vaccinees ( ...
Table 2
Serum LPS antibody responses to S. Typhi, S. Paratyphi A, and S. Paratyphi B

Serum IgG anti-LPS Ab titer measurements were also performed against all three LPS preparations. Similar to the results observed with IgA, significantly elevated IgG anti-LPS levels were observed on days 7 and 42 postvaccination compared to the corresponding prevaccination levels. However, as shown in Fig. 3B, in contrast to the observations with IgA (Fig. 3A), the postvaccination fold increases of anti-LPS IgA Ab titers did not decline markedly from day 7 to day 42. The seroconversion rates for IgG anti-LPS Ab titers against S. Typhi (9 out of 17; 53%), S. Paratyphi A (6 out of 17; 35%), and S. Paratyphi B (5 out of 17; 29%) were not significantly different. No differences were observed in the mean ± SE of the peak postvaccination IgG LPS Ab fold increases for S. Typhi, S. Paratyphi A, and S. Paratyphi B (Table 2).

Taken together, these anti-LPS serological results indicate the lack of statistically significant differences when considering either fold increases, seroconversion rates, or mean titers (data not shown) in IgA or IgG to S. Typhi, S. Paratyphi A, and S. Paratyphi B LPS (Table 2).

Induction of IgA BM cells to S. Typhi, S. Paratyphi A, and S. Paratyphi B LPS and OMP, measured by ELISpot assay, in Ty21a vaccinees.

The induction of antigen-specific BM cells, which can be measured in cryopreserved PBMC, is now considered to be a widely accepted immunological tool to study the long-term humoral immunity elicited following vaccination or natural infection (7, 26, 58, 59, 71). Therefore, it was of importance to determine whether Ty21a immunization elicits IgA BM anti-LPS and anti-OMP responses that are cross-reactive among LPS and OMP preparations from S. Typhi, S. Paratyphi A, and S. Paratyphi B. Study specimens were collected before (day 0) and after (days 42, 84, and 180) immunization to determine the persistence of BM responses. As shown in Fig. 4A, LPS-specific IgA BM responses were induced against all 3 LPS preparations. The mean peak frequencies of IgA LPS-specific BM responses for S. Typhi and S. Paratyphi B were significantly elevated from their corresponding prevaccination levels, while the postvaccination rises for S. Paratyphi A showed a strong trend but did not reach statistical significance (Fig. 4A). The dominant postvaccination responses were directed toward S. Typhi LPS and were significantly higher than those observed against both S. Paratyphi A and B (Fig. 4A). No significant differences were observed between peak responses to S. Paratyphi A and S. Paratyphi B (P = 0.15). Similarly, when the net postvaccination increases were calculated by subtracting the prevaccination level in each volunteer from the respective postvaccination peak frequencies, significantly higher postvaccination levels were observed toward S. Typhi LPS than toward S. Paratyphi A or S. Paratyphi B (Fig. 4B and Table 3). Net postvaccination increases to S. Paratyphi B were not significantly higher than those directed to S. Paratyphi A (Fig. 4B and Table 3). The percentage of IgA BM cell-positive responders for S. Typhi (9 out of 16; 56%) showed a trend but was not significantly different from those for S. Paratyphi A (5 out of 16; 31%) or S. Paratyphi B (6 out of 16; 38%).

Fig 4
B memory (BM) responses in Ty21a vaccinees, showing specific IgA BM responses for LPS from S. Typhi, S. Paratyphi A (Para A), and S. Paratyphi B (Para B) following vaccination with Ty21a (n = 15). Shown are prevaccination (day 0; open bars) and postvaccination ...
Table 3
IgA BM responses to S. Typhi, S. Paratyphi A, and S. Paratyphi B

Outer membrane proteins (OMPs), which include porins of Gram-negative bacteria, are highly immunogenic. Therefore, IgA BM responses specific to the OMP preparations described in Materials Methods were also measured. As shown in Fig. 5A, OMP-specific IgA BM responses were elicited against all three OMP preparations, as evidenced by significant or very strong trends in increased responses in postvaccination peak levels compared to the corresponding prevaccination levels. Interestingly, unlike observations with LPS, the peak responses directed to S. Typhi OMP were similar in magnitude to those against S. Paratyphi B OMP (Fig. 5A). In contrast, IgA BM-specific OMPs from both S. Typhi and S. Paratyphi B were significantly higher than those against S. Paratyphi A (Fig. 5A).

Fig 5
B memory (BM) responses in Ty21a vaccinees, showing specific IgA BM responses for outer membrane protein (OMP) from S. Typhi, S. Paratyphi A (Para A), and S. Paratyphi B (Para B) following vaccination with Ty21a (n = 16). Shown are prevaccination (day ...

Similar results were observed when analyzing net increases in postvaccination peak BM responses specific for S. Typhi and S. Paratyphi B (Fig. 5B and Table 3). Net increases to S. Paratyphi A were significantly lower than those to S. Typhi, while only a trend to exhibit lower net increases was observed when comparing responses to S. Paratyphi A and S. Paratyphi B (Fig. 5B and Table 3). The percentage of IgA BM-positive responders to OMP for S. Typhi (13 out of 16; 81%) was not significantly different from that to S. Paratyphi A (10 out of 16; 63%) or S. Paratyphi B (11 out of 16; 69%).

Taken together, these results suggest that the IgA BM responses to LPS and OMP follow the general trend of the strongest responses being observed against S. Typhi, followed by S. Paratyphi B and then S. Paratyphi A.

Induction of IgA and IgG BM cells to S. Typhi, S. Paratyphi A, and S. Paratyphi B LPS and OMP, determined by ALS assay, in Ty21a vaccinees.

The measurement of antigen-specific Ab in supernatants of expanded cultures can be used as a proxy for the presence of BM cells, especially in situations where there are limitations in cell availability. This has been validated in a few studies, including our own, which reported positive correlations of LPS responses between antibody-in-culture-supernatant (ALS) and BM ELISpot assays (26, 71). In the present studies we observed similar correlations between BM and ALS assays with OMP preparations (see Fig. S2 in the supplemental material). Because of cell limitations, we were unable to measure IgG antigen-specific BM by ELISpot assay in this study. However, sufficient culture supernatants were available from 15 of 16 subjects to enable the measurement of IgG and IgA to LPS by ALS assay. No significant differences were observed in the percentages of IgA responders to S. Typhi, S. Paratyphi A, and S. Paratyphi B LPS (Fig. 6A). Except in a few volunteers, the levels of IgG anti-LPS were below the detection level. Only 20 to 25% of the subjects were found to be IgG responders to the LPS preparations by ALS assay (Fig. 6A). In contrast, both IgA and IgG Ab to all three OMP preparations were observed in most volunteers by ALS assays. However, no significant differences in the percentage of IgA and IgG responders to any of the three strain-specific OMP preparations were observed (Fig. 6B).

Fig 6
Percentages of responders for LPS (A) and OMP (B) from S. Typhi-, S. Paratyphi A-, and S. Paratyphi B-specific antibody in culture supernatants (ALS) among Ty21a vaccinees (n = 15). Responders were defined as those with at least a 2-fold rise in antibody ...

DISCUSSION

Results from prospective, randomized, placebo-controlled large-scale field trials demonstrate that Ty21a oral typhoid vaccine can protect against S. Paratyphi B (3, 37) but not against S. Paratyphi A (57). We undertook to determine whether cross-reacting immune responses to S. Paratyphi B and A can explain the observed differences, beginning with a detailed analysis of humoral B cell responses.

Vaccines typically protect from disease and/or infection by eliciting effector immunity and immunological memory (38) and have the potential to elicit cross-protection to related organisms if they express similar protective antigens. For example, these serovars share some O antigenic determinants, e.g., O antigen (37, 40), and some of the proteins expressed in these Salmonella species, e.g., OmpC and OmpF, share a considerably degree of homology (46).

Three doses of Ty21a in enteric-coated capsules have been shown to confer 62% protective efficacy against typhoid fever over a period of 7 years of follow-up (35). The identification of the protective antigens and immune mechanisms responsible for protection following Ty21a vaccination is severely limited by the fact that S. Typhi is a human-restricted pathogen, which limits these studies to humans. In spite of these restrictions, extensive studies on the immunological responses elicited by typhoid vaccines were carried out in subjects immunized with Ty21a, as well as other novel vaccine candidates (31, 39, 41, 5054, 6163, 6669, 7173). Although these studies have advanced our knowledge on the humoral and cell-mediated immune responses elicited by this vaccine, the “true” effector immunological mechanisms responsible for protection remain elusive. Nevertheless, the appearance of LPS-specific ASC in circulation and of serum Ab following vaccination with Ty21a has been proposed as a surrogate of protection based on the observation that their magnitudes increase with the number of doses administered (27), a fact that tracks the protective efficacy with increasing doses of Ty21a in field trials (14). Thus, the present study was directed to uncover the immunological mechanisms which could explain the observed cross-protection in Ty21a vaccinees against S. Paratyphi B, but not S. Paratyphi A, by focusing on adaptive humoral immune responses to these 3 Salmonella serovars. These studies might also provide important information to accelerate the development of S. Paratyphi A vaccines.

Our results on the induction of IgA and IgG LPS ASC following immunization with Ty21a showed that the magnitude of these responses was significantly higher to S. Typhi than to either S. Paratyphi A or S. Paratyphi B. Interestingly, the IgA LPS ASC responses to S. Paratyphi B were significantly higher than those to S. Paratyphi A, but only a similar trend was observed in IgG LPS ASC. It is possible that the latter trend in LPS IgG ASC was the result of the relatively limited number of subjects evaluated. Future studies with increased numbers of volunteers should establish the validity of this argument. The observed induction of predominantly mucosal IgA ASC is similar to that previously reported with Ty21a and other attenuated candidate typhoid vaccines (28, 31, 6668, 71). However, to our knowledge this study is the first to demonstrate cross-reactive IgA ASC responses to S. Paratyphi A and S. Paratyphi B LPS following Ty21a vaccination.

Serum antibody responses to LPS and other S. Typhi antigens also traditionally have been measured in the study of immunogenicity of Ty21a and other candidate typhoid vaccines (15, 31, 34, 61, 64, 66, 70, 71). Although in a few reports serum Ab to S. Typhi have been demonstrated to kill Salmonella ex vivo (21, 39, 69), this is unlikely to represent the ultimate operative mechanism of protection. In the present study, the kinetics of Ab responses to LPS were similar to our previous observations with S. Typhi candidate vaccine CVD 909 (71); however, no differences were observed in the kinetics of induction of serum IgG or IgA antibodies to LPS from S. Typhi, S. Paratyphi A, and S. Paratyphi B (in either magnitude, percentage of responders, fold increases, or persistence).

The cross-reactive humoral responses to LPS are likely directed toward shared O antigen 12, the trisaccharide (mannose-rhamnose-galactose) repeating unit that comprises the backbone common to Salmonella groups A, B, and D. A hexose linked to the mannose residue comprises the immunodominant epitope that results in serogroup specificity. This hexose is a paratose in group A, an abequose in group B, and a tyvelose in group D. However, the trisaccharide repeat backbone (O antigen 12) is identical among the three O serogroups (37, 40). Ty21a is mutated in the gene for the UDP-galactose-4-epimerase; consequently, Ty21a cannot de novo synthesize smooth O polysaccharide (OPS). However, if provided exogenous galactose, it can make smooth LPS. Thus, Ty21a is grown in fermentors in broth containing 0.01% galactose (17). Additional galactose may be scavenged in the human intestinal tract. Some cross-reactive ASC and serum antibody responses may also be directed against epitopes of the core polysaccharide, which is common to all Salmonella serovars. However, the lack of cross-protection against S. Paratyphi A in the field trials argues against the possibility that these cross-reactive shared epitopes play a critical role in cross-protection. Of note, Ab against the trisaccharide backbone also demonstrate lower protection in animal models than those directed to the serogroup OPS-specific epitopes (6). Taken together, these results support the contention that the minor differences observed between ASC and antibody responses to S. Paratyphi A and S. Paratyphi B LPS are unlikely to provide an immunological basis for the lack of cross-protection from S. Paratyphi A infection observed in the field trials.

We also explored whether the differences in the observed cross-protection to S. Paratyphi B, but not S. Paratyphi A, might be found in differences in the homing potentials of anti-LPS BM cell subsets elicited by Ty21a immunization. It has been shown that following oral Ty21a vaccination, circulating ASC in peripheral blood expressed the integrin α4β7 gut homing receptor (29, 47). However, largely due to technical limitations, our knowledge of the relative proportions of ASC homing to the gut and to peripheral lymphoid tissues is rather limited. The CD27 molecule is present in B cells that have undergone the process of hypermutation after encountering antigens, and therefore it is expressed in ASC and BM cells (1, 32). Regarding homing, CD62L (L-selectin) is required by leukocytes to enter secondary lymphoid tissues via high endothelial venules, while integrin α4β7 is a key molecule involved in gut homing (2, 4, 56). Thus, ASC populations (CD19+ CD27+) which express integrin α4β7, but not CD62L, are effector B cells that are destined to migrate exclusively to the gut mucosa, whereas cells expressing CD62L but not integrin α4β7 are destined to home to secondary lymphoid tissues. Although the homing potential and the activity of ASC and BM cells that express both integrin α4β7 and CD62L population are not very well understood, previous studies have suggested that that they have the potential to migrate to both gut and peripheral lymph nodes (4, 25).

To uncover the phenotypic and homing characteristics of S. Typhi LPS-specific ASC elicited by Ty21a immunization, we developed a novel approach to study the proportions of specific ASC which exhibit the characteristics of B naive or ASC/BM cells and that have the potential to home to secondary lymphoid tissues and/or gut by flow cytometric cell sorting. The results clearly indicate that the vast majority of both IgA and IgG anti-S. Typhi LPS-specific ASC express the gut homing molecule integrin α4β7 in the absence of CD62L. Importantly, we observed for the first time that a significant proportion of these specific ASC are also endowed with the capacity to home to both the gut and peripheral secondary lymphoid tissues, including peripheral lymphoid tissues. Only a very small minority of LPS-specific ASC express exclusively CD62L. The fact that we observed identical homing patterns in ASC cross-reactive to S. Paratyphi A and S. Paratyphi B strongly suggests that differences in the homing patterns of IgG and IgA anti-LPS ASC are unlikely to explain the differences in cross-protection to S. Paratyphi B and S. Paratyphi A observed in epidemiological studies.

Vaccines protect from infection or disease by eliciting effector immune responses as well as by the generation of T and B memory cells, which are primarily responsible for the longevity of the response (55). The recent development of a technique to measure BM cells in PBMC has been used to further evaluate and understand the protective immune memory induced by vaccines or natural infections (8, 19, 26, 58, 59, 71). We have previously demonstrated that Ty21a vaccination is capable of eliciting IgA BM responses to the T-independent antigen LPS and both IgA and IgG BM responses to T-dependent protein antigens (71).

To evaluate whether differences in the induction of BM cells to S. Typhi, S. Paratyphi A, and S. Paratyphi B could be responsible for the observed cross-protection between S. Typhi and S. Paratyphi B, we measured the induction of BM responses to both T-independent (i.e., LPS) and T-dependent (e.g., outer membrane protein [OMP]) antigens from these Salmonella serovars in Ty21a vaccinees. OMPs were selected for several reasons. OMPs have been demonstrated to elicit persistent antibody responses against S. Typhi in mice (2224). Moreover, rises in serum antiporin antibody titers have been observed in healthy volunteers vaccinated with porins and following typhoid fever infections (5). Based on these findings, these proteins have been proposed as candidate vaccines against typhoid fever (49).

Previous studies have shown that immunity elicited by oral vaccination or infection elicits predominantly IgA responses (19, 58, 60). Thus, due to limitations in specimen availability, we performed B cell ELISpot assays to measure IgA BM only. However, the IgG BM responses were measured using ALS assays, which have shown to be a reliable alternative for measuring BM responses (26, 30, 71). Of note, in the current study we observed very strong correlations between the data for IgA to OMP determined by ALS and the BM data determined by ELISpot, confirming the concordance between these 2 BM cell assays and the validity of the data obtained by using these two different methods.

We observed that Ty21a induced predominantly IgA BM responses against S. Typhi LPS and OMP. However, in spite of the fact that cross-reactivity against both S. Paratyphi A and S. Paratyphi B LPS was apparent, no significant differences were observed in these BM responses. In contrast, OMP-specific BM responses elicited by immunization with Ty21a were similar against both S. Typhi and S. Paratyphi B but lower against S. Paratyphi A. However, no significant differences in the proportion of responders were observed against LPS from the 3 Salmonella serovars. Of note, IgG BM responses against LPS antigens from all three strains were detectable in just a few individuals. This low proportion of IgG BM responders for T-I antigens (e.g., LPS and Vi polysaccharide) is similar to that previously observed with oral vaccination with Ty21a or CVD 909 but not with T-D antigens such as flagella (71). It could be argued that T-I antigens are less potent in inducing long-term IgG BM responses and that the oral route preferentially induces mucosal immune responses.

In sum, the evidence presented in this report supports the notion that humoral responses to key antigens (LPS and OMP) do not play the dominant role in the cross-protective immunity observed between S. Typhi and S. Paratyphi B, but not S. Paratyphi A, following Ty21a immunization. However, we cannot rule out that other related humoral responses not measured in this study, such as antibody responses to other Salmonella serovar common antigens (e.g., flagella or core OPS), or the functional ability of antibodies (e.g., avidity, opsonophagocytic, and serum bactericidal activity) plays a role in cross-protection. We are currently performing assays on the functional antibody immune responses induced by Ty21a against S. Paratyphi A and S. Paratyphi B to investigate whether they could explain the lack of correlation of the measured humoral responses and protection in field studies.

An important aspect of the pathogenesis of enteric fevers is S. Typhi's ability to survive and replicate intracellularly in its dissemination and persistence in the host (44, 74). Thus, it is likely that CMI plays a key role, maybe the dominant role, in protection from S. Typhi infection. In fact, a growing body of literature shows that oral immunization of subjects with Ty21a and other attenuated S. Typhi vaccine candidates elicits a wide array of specific effector and memory T cell responses, including, among others, proliferative responses, proinflammatory cytokines, and cytotoxic T lymphocytes restricted by classical and HLA-E major histocompatibility complex (MHC) molecules (31, 41, 4954, 6163, 6568, 72, 73, 75), that might underlie the long-term efficacy of the Ty21a vaccine. Further studies directed to evaluate whether differences in CMI to S. Typhi, S. Paratyphi A, and S. Paratyphi B antigenic stimulation are observed following Ty21a immunization might provide a mechanistic basis for the observed cross-protection between S. Typhi and S. Paratyphi B elicited by Ty21a. This has the potential to dramatically accelerate the development of broad-spectrum live oral vaccines against the major etiologic agents causing enteric fever. One could envision the development of a bivalent vaccine consisting of an attenuated strain to prevent S. Typhi and S. Paratyphi B disease and another to prevent S. Paratyphi A disease. Such a vaccine would be much simpler to develop, manufacture, and ensure consistency for than a trivalent vaccine.

Supplementary Material

Supplemental material:

ACKNOWLEDGMENTS

We are indebted to the volunteers who allowed us to perform this study. We thank Regina Harley for outstanding technical support.

This paper includes work funded, in part, by NIAID, NIH, DHHS grants R01-AI036525 (to M.B.S.), U19 AI082655 (Cooperative Center for Translational Research in Human Immunology and Biodefense [CCHI]) (to M.B.S.), and U54-AI057168 (Regional Center for Excellence for Biodefense and Emerging Infectious Diseases Research Mid-Atlantic Region [MARCE]) (to M.M.L.).

The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.

Footnotes

Published ahead of print 4 April 2012

Supplemental material for this article may be found at http://cvi.asm.org/.

REFERENCES

1. Agematsu K, Hokibara S, Nagumo H, Komiyama A. 2000. CD27: a memory B-cell marker. Immunol. Today 21: 204–206. [PubMed]
2. Bargatze RF, Jutila MA, Butcher EC. 1995. Distinct roles of L-selectin and integrins alpha 4 beta 7 and LFA-1 in lymphocyte homing to Peyer's patch-HEV in situ: the multistep model confirmed and refined. Immunity 3: 99–108. [PubMed]
3. Black RE, et al. 1990. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee. Vaccine 8: 81–84. [PubMed]
4. Brandtzaeg P, Johansen FE. 2005. Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties. Immunol. Rev. 206: 32–63. [PubMed]
5. Calderon I, et al. 1986. Antibodies to porin antigens of Salmonella typhi induced during typhoid infection in humans. Infect. Immun. 52: 209–212. [PMC free article] [PubMed]
6. Carlin NI, Svenson SB, Lindberg AA. 1987. Role of monoclonal O-antigen antibody epitope specificity and isotype in protection against experimental mouse typhoid. Microb. Pathog. 2: 171–183. [PubMed]
7. Crotty S, Aubert RD, Glidewell J, Ahmed R. 2004. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J. Immunol. Methods 286: 111–122. [PubMed]
8. Crotty S, et al. 2003. Long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171: 4969–4973. [PubMed]
9. Crump JA, Luby SP, Mintz ED. 2004. The global burden of typhoid fever. Bull. World Health Organ. 82: 346–353. [PubMed]
10. Crump JA, Mintz ED. 2010. Global trends in typhoid and paratyphoid fever. Clin. Infect. Dis. 50: 241–246. [PMC free article] [PubMed]
11. Darveau RP, Hancock RE. 1983. Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and Salmonella typhimurium strains. J. Bacteriol. 155: 831–838. [PMC free article] [PubMed]
12. El-Kamary SS, et al. 2010. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202: 1649–1658. [PubMed]
13. Fangtham M, Wilde H. 2008. Emergence of Salmonella paratyphi A as a major cause of enteric fever: need for early detection, preventive measures, and effective vaccines. J. Travel Med. 15: 344–350. [PubMed]
14. Ferreccio C, Levine MM, Rodriguez H, Contreras R. 1989. Comparative efficacy of two, three, or four doses of Ty21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J. Infect. Dis. 159: 766–769. [PubMed]
15. Forrest BD, LaBrooy JT, Beyer L, Dearlove CE, Shearman DJ. 1991. The human humoral immune response to Salmonella typhi Ty21a. J. Infect. Dis. 163: 336–345. [PubMed]
16. Gat O, et al. 2011. Cell-associated flagella enhance the protection conferred by mucosally-administered attenuated Salmonella paratyphi a vaccines. PLoS Negl. Trop. Dis. 5: e1373 doi:10.1371/journal.pntd.0001373. [PMC free article] [PubMed]
17. Germanier R, Fuer E. 1975. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. 131: 553–558. [PubMed]
18. Gupta SK, et al. 2008. Laboratory-based surveillance of paratyphoid fever in the United States: travel and antimicrobial resistance. Clin. Infect. Dis. 46: 1656–1663. [PubMed]
19. Harris AM, et al. 2009. Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect. Immun. 77: 3850–3856. [PMC free article] [PubMed]
20. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ. 2000. Repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2. J. Immunol. 165: 618–622. [PubMed]
21. Hone DM, et al. 1988. A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans. Infect. Immun. 56: 1326–1333. [PMC free article] [PubMed]
22. Isibasi A, et al. 1988. Protection against Salmonella typhi infection in mice after immunization with outer membrane proteins isolated from Salmonella typhi 9,12,d, Vi. Infect. Immun. 56: 2953–2959. [PMC free article] [PubMed]
23. Isibasi A, et al. 1992. Active protection of mice against Salmonella typhi by immunization with strain-specific porins. Vaccine 10: 811–813. [PubMed]
24. Isibasi A, et al. 1994. Role of porins from Salmonella typhi in the induction of protective immunity. Ann. N. Y. Acad. Sci. 730: 350–352. [PubMed]
25. Jaimes MC, et al. 2004. Maturation and trafficking markers on rotavirus-specific B cells during acute infection and convalescence in children. J. Virol. 78: 10967–10976. [PMC free article] [PubMed]
26. Jayasekera CR, et al. 2008. Cholera toxin-specific memory B cell responses are induced in patients with dehydrating diarrhea caused by Vibrio cholerae O1. J. Infect. Dis. 198: 1055–1061. [PMC free article] [PubMed]
27. Kantele A. 1990. Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. Vaccine 8: 321–326. [PubMed]
28. Kantele A, Arvilommi H, Kantele JM, Rintala L, Makela PH. 1991. Comparison of the human immune response to live oral, killed oral or killed parenteral Salmonella typhi TY21A vaccines. Microb. Pathog. 10: 117–126. [PubMed]
29. Kantele A, Westerholm M, Kantele JM, Makela PH, Savilahti E. 1999. Homing potentials of circulating antibody-secreting cells after administration of oral or parenteral protein or polysaccharide vaccine in humans. Vaccine 17: 229–236. [PubMed]
30. Kirkpatrick BD, et al. 2005. Comparison of the antibodies in lymphocyte supernatant and antibody-secreting cell assays for measuring intestinal mucosal immune response to a novel oral typhoid vaccine (M01ZH09). Clin. Diagn. Lab. Immunol. 12: 1127–1129. [PMC free article] [PubMed]
31. Kirkpatrick BD, et al. 2005. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. J. Infect. Dis. 192: 360–366. [PubMed]
32. Klein U, Rajewsky K, Kuppers R. 1998. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J. Exp. Med. 188: 1679–1689. [PMC free article] [PubMed]
33. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. 1996. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14: 435–438. [PubMed]
34. Kollaritsch H, et al. 2000. Local and systemic immune responses to combined Vibrio cholerae CVD103-HgR and Salmonella typhi ty21a live oral vaccines after primary immunization and reimmunization. Vaccine 18: 3031–3039. [PubMed]
35. Levine MM, et al. 1999. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 17(Suppl. 2): S22–S27. [PubMed]
36. Levine MM, Ferreccio C, Black RE, Germanier R. 1987. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet i: 1049–1052. [PubMed]
37. Levine MM, et al. 2007. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin. Infect. Dis. 45(Suppl. 1): S24–S28. [PubMed]
38. Levine MM, Sztein MB. 2004. Vaccine development strategies for improving immunization: the role of modern immunology. Nat. Immunol. 5: 460–464. [PubMed]
39. Lindow JC, Fimlaid KA, Bunn JY, Kirkpatrick BD. 2011. Antibodies in action: role of human opsonins in killing Salmonella enterica serovar Typhi. Infect. Immun. 79: 3188–3194. [PMC free article] [PubMed]
40. Liu D, Verma NK, Romana LK, Reeves PR. 1991. Relationships among the rfb regions of Salmonella serovars A, B, and D. J. Bacteriol. 173: 4814–4819. [PMC free article] [PubMed]
41. Lundin BS, Johansson C, Svennerholm AM. 2002. Oral immunization with a Salmonella enterica serovar typhi vaccine induces specific circulating mucosa-homing CD4(+) and CD8(+) T cells in humans. Infect. Immun. 70: 5622–5627. [PMC free article] [PubMed]
42. Meltzer E, Sadik C, Schwartz E. 2005. Enteric fever in Israeli travelers: a nationwide study. J. Travel Med. 12: 275–281. [PubMed]
43. Meltzer E, Schwartz E. 2010. Enteric fever: a travel medicine oriented view. Curr. Opin. Infect. Dis. 23: 432–437. [PubMed]
44. Merrell DS, Falkow S. 2004. Frontal and stealth attack strategies in microbial pathogenesis. Nature 430: 250–256. [PubMed]
45. Nikaido H. 1983. Proteins forming large channels from bacterial and mitochondrial outer membranes: porins and phage lambda receptor protein. Methods Enzymol. 97: 85–100. [PubMed]
46. Nikaido H. 2003. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. 67: 593–656. [PMC free article] [PubMed]
47. Pakkanen SH, et al. 2010. Expression of homing receptors on IgA1 and IgA2 plasmablasts in blood reflects differential distribution of IgA1 and IgA2 in various body fluids. Clin. Vaccine Immunol. 17: 393–401. [PMC free article] [PubMed]
48. Parry CM, Threlfall EJ. 2008. Antimicrobial resistance in typhoidal and nontyphoidal salmonellae. Curr. Opin. Infect. Dis. 21: 531–538. [PubMed]
49. Salazar-Gonzalez RM, et al. 2004. Induction of cellular immune response and anti-Salmonella enterica serovar typhi bactericidal antibodies in healthy volunteers by immunization with a vaccine candidate against typhoid fever. Immunol. Lett. 93: 115–122. [PubMed]
50. Salerno-Goncalves R, Fernandez-Vina M, Lewinsohn DM, Sztein MB. 2004. Identification of a human HLA-E-restricted CD8+ T cell subset in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. J. Immunol. 173: 5852–5862. [PubMed]
51. Salerno-Goncalves R, Pasetti MF, Sztein MB. 2002. Characterization of CD8(+) effector T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. J. Immunol. 169: 2196–2203. [PubMed]
52. Salerno-Goncalves R, Sztein MB. 2006. Cell-mediated immunity and the challenges for vaccine development. Trends Microbiol. 14: 536–542. [PubMed]
53. Salerno-Goncalves R, Wahid R, Sztein MB. 2005. Immunization of volunteers with Salmonella enterica serovar Typhi strain Ty21a elicits the oligoclonal expansion of CD8+ T cells with predominant Vbeta repertoires. Infect. Immun. 73: 3521–3530. [PMC free article] [PubMed]
54. Salerno-Goncalves R, et al. 2003. Concomitant induction of CD4+ and CD8+ T cell responses in volunteers immunized with Salmonella enterica serovar typhi strain CVD 908-htrA. J. Immunol. 170: 2734–2741. [PubMed]
55. Sallusto F, Lanzavecchia A, Araki K, Ahmed R. 2010. From vaccines to memory and back. Immunity 33: 451–463. [PubMed]
56. Shyjan AM, Bertagnolli M, Kenney CJ, Briskin MJ. 1996. Human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) demonstrates structural and functional similarities to the alpha 4 beta 7-integrin binding domains of murine MAdCAM-1, but extreme divergence of mucin-like sequences. J. Immunol. 156: 2851–2857. [PubMed]
57. Simanjuntak CH, et al. 1991. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 338: 1055–1059. [PubMed]
58. Simon JK, et al. 2011. Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates. Clin. Immunol. 139: 185–192. [PMC free article] [PubMed]
59. Simon JK, et al. 2009. Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates. Vaccine 27: 565–572. [PubMed]
60. Sundstrom P, Lundin SB, Nilsson LA, Quiding-Jarbrink M. 2008. Human IgA-secreting cells induced by intestinal, but not systemic, immunization respond to CCL25 (TECK) and CCL28 (MEC). Eur.J. Immunol. 38: 3327–3338. [PubMed]
61. Sztein MB. 2007. Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica serovar Typhi strains used as live oral vaccines in humans. Clin. Infect. Dis. 45(Suppl. 1): S15–S19. [PubMed]
62. Sztein MB, Tanner M, Polotsky Y, Orenstein JM, Levine MM. 1995. Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella typhi in humans. J. Immunol. 155: 3987–3993. [PubMed]
63. Sztein MB, et al. 1994. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J. Infect. Dis. 170: 1508–1517. [PubMed]
64. Tacket CO, et al. 1986. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J. Infect. Dis. 154: 342–345. [PubMed]
65. Tacket CO, Levine MM. 2007. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clin. Infect. Dis. 45(Suppl. 1): S20–S23. [PubMed]
66. Tacket CO, Pasetti MF, Sztein MB, Livio S, Levine MM. 2004. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. J. Infect. Dis. 190: 565–570. [PubMed]
67. Tacket CO, et al. 1997. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect. Immun. 65: 452–456. [PMC free article] [PubMed]
68. Tacket CO, et al. 2000. Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect. Immun. 68: 1196–1201. [PMC free article] [PubMed]
69. Tagliabue A, et al. 1986. IgA-driven T cell-mediated anti-bacterial immunity in man after live oral Ty 21a vaccine. J. Immunol. 137: 1504–1510. [PubMed]
70. Viret JF, et al. 1999. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Infect. Immun. 67: 3680–3685. [PMC free article] [PubMed]
71. Wahid R, et al. 2011. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans. Clin. Immunol. 138: 187–200. [PMC free article] [PubMed]
72. Wahid R, Salerno-Goncalves R, Tacket CO, Levine MM, Sztein MB. 2007. Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909. Vaccine 25: 1416–1425. [PMC free article] [PubMed]
73. Wahid R, Salerno-Goncalves R, Tacket CO, Levine MM, Sztein MB. 2008. Generation of specific effector and memory T cells with gut- and secondary lymphoid tissue-homing potential by oral attenuated CVD 909 typhoid vaccine in humans. Mucosal Immunol. 1: 389–398. [PMC free article] [PubMed]
74. Weinstein DL, O'Neill BL, Hone DM, Metcalf ES. 1998. Differential early interactions between Salmonella enterica serovar Typhi and two other pathogenic Salmonella serovars with intestinal epithelial cells. Infect. Immun. 66: 2310–2318. [PMC free article] [PubMed]
75. Wyant TL, Tanner MK, Sztein MB. 1999. Potent immunoregulatory effects of Salmonella typhi flagella on antigenic stimulation of human peripheral blood mononuclear cells. Infect. Immun. 67: 1338–1346. [PMC free article] [PubMed]

Articles from Clinical and Vaccine Immunology : CVI are provided here courtesy of American Society for Microbiology (ASM)